Hologic — Jul 30, 2025 release

Financial Guidance for the Fourth Quarter and Full Fiscal Year 2025 “Building on our solid third-quarter performance, in the fourth quarter we continue to expect mid-single-digit growth in organic, constant currency revenue excluding COVID,” said Karleen Oberton, Hologic’s Chief Financial Officer.  “We also forecast non-GAAP earnings per share will grow faster than revenue, helped in part by our tariff mitigation efforts.” Hologic’s financial guidance for the fourth quarter and full year 2025 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.25%, and diluted shares outstanding of approximately 228 million for the full year.  Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2025 as in fiscal 2024.  Organic revenue guidance for fiscal 2025 is in constant currency and excludes the divested blood screening and SSI ultrasound imaging businesses.  Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition.  In fiscal 2025, revenue from the acquired Endomagnetics business becomes organic in August.  Revenue from the acquired Gynesonics business will be excluded from organic revenue for all of fiscal 2025.  Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue and COVID-19 related revenue.     Current Guidance     Previous Guidance       Guidance $   Reported % Increase (Decrease)